目錄:MedChemExpress LLC>>信號(hào)通路>> Tandutinib | 坦度替尼 | MedChemExpress (MCE)
參考價(jià) | ¥ 605 |
參考價(jià) | ¥ 605 |
更新時(shí)間:2024-01-10 11:18:56瀏覽次數(shù):137評(píng)價(jià)
聯(lián)系我們時(shí)請(qǐng)說明是化工儀器網(wǎng)上看到的信息,謝謝!
CAS | 387867-13-2 | 純度 | 99.48% |
---|---|---|---|
分子量 | 562.7 | 分子式 | C??H??N?O? |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 10 mM * 1 mL |
貨號(hào) | HY-10202 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。
CAS No. : 387867-13-2
MCE 國際站:Tandutinib
產(chǎn)品活性:Tandutinib (MLN518) 是一種有效和選擇性的 FLT3 的抑制劑,其 IC50 為 0.22 μM,并且還抑制 c-Kit 和 PDGFR,其 IC50 分別為 0.17 μM 和 0.20 μM。Tandutinib 可用于急性骨髓性白血病,并具有穿越血腦屏障的能力。
研究領(lǐng)域:Protein Tyrosine Kinase/RTK | Apoptosis
作用靶點(diǎn):FLT3 | c-Kit | PDGFR | Apoptosis
In Vitro: Tandutinib (0-3 μM; 30 minutes; Ba/F3 cells) treatment inhibits IL-3-independent cell growth and FLT3-ITD autophosphorylation with an IC50 of 10-100 nM in Ba/F3 cells expressing different FLT3-ITD mutants.
Tandutinib (1 μM; 24-96 hours; Molm-14 and THP-1 AML cells) treatment induces apoptosis in FLT3-ITD-positive AML cells.
In human FLT3-ITD-positive AML cell lines, Tandutinib inhibits FLT3-ITD phosphorylation (IC50 of ~30 nM). As with Erk2, a constitutively high level of Akt phosphorylation is readily detected and is efficiently blocked by pretreatment of the Molm-14 cells with 100-300 nM Tandutinib.
Tandutinib inhibits cell proliferation of the FLT3-ITD-positive Molm-13 and Molm-14 with an IC50 of 10 nM. And signaling through the MAP kinase and PI3 kinase pathways.
In Vivo: Tandutinib (60 mg/kg; oral gavage; daily; for 35 days; athymic nude mice) treatment causes a statistically significant increase in survival that was extended on average by 20 days.
相關(guān)產(chǎn)品:Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Apoptosis Compound Library | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | Anti-Cancer Compound Library | Clinical Compound Library | CNS-Penetrant Compound Library | Drug Repurposing Compound Library | Reprogramming Compound Library | Anti-Blood Cancer Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Highly Selective Activators Library | Cytokine Inhibitors Library | Cell Death Library | MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | LY294002 | Tamoxifen | Paclitaxel | Y-27632 | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | SB-431542 | Actinomycin D | Deferoxamine mesylate | Bortezomib | 5-Fluorouracil | Trametinib | Sorafenib | Oxaliplatin | Gemcitabine | Temozolomide | Rotenone | Mdivi-1 | Elesclomol | Ruxolitinib | Decitabine | SP600125 | MK-2206 dihydrochloride | Etoposide | Monomethyl auristatin E
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標(biāo)記物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)